Ohio State Navbar

Education

Diabetes Dialogue Series 2013


The Diabetes Dialogue is a series formulated to provide the latest breakthroughs in diabetes research and clinical practice to the medical community. In particular, the meeting will focus on non-pharmacological intervention in the management of obesity and diabetes.While there is no doubt that medication treatment is effective in most patients, it is also clear that it is extremely difficult to achieve the American Diabetes Association Recommended AIC goal of less that 7% in most patients. Alternative approaches are needed to complement the medication treatment of patients with diabetes.

The primary goals of diabetes care are to maintain health, prevent long term complications and prevent hypoglycemia. In this regard, the fear of hypoglycemia has limited the ability for most of our patients to achieve normal glucose control as assessed by A1C. Indeed, with innovations in new insulin and oral medications, the A1C has decreased from 9.1% to 8.1%. In addition, for the past 2 decades, the life expectancy gap between patients with diabetes and non – diabetic subjects has narrowed by 15 years and mortality has decreased by 43%. However, there are concerns that better technology will be needed to essentially normalize the A1C and further reduce the mortality gap. These technological advances will depend on new innovations such as new insulin delivery devices, remote glucose sensors and monitors and new technologies in islet cell transplantation or tissue replacement. Ultimately, physiologic replacement of insulin will be necessary to ensure normalization of glucose control without hypoglycemia using tissue insulin delivery therapies.

The Ohio State University Medical Center, Center for Continuing Medical Education (CCME) is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians. The Ohio State University Medical Center, Center for Continuing Medical Education designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

2013 Diabetes Dialogue:

Innovations in Diabetes Technologies and Diabetes Care: April 25th, 2013

  • Identify the insulin delivery devices.
  • Explain the use of glucose sensing devices.
  • Assess the indications of prescribing insulin delivery and glucose sensing devices.
  • Recognize limitations of both insulin delivery and glucose sensing devices.

 Application of glucose sensing in inpatient and outpatient settings: June 13th, 2013

  • Identify appropriate candidates for continuous glucose monitoring.
  • Describe benefits and limkitations for continuous glucose monitoring.
  • Outline applications for continuous glucose monitoring in the hospital.
Benefit of Multiple Dose Insulin v/s Insulin Pump: September 12th, 2013
  • List benefits and limitations of Insulin Pumps
  • Identify Clinical Practice and Pitfalls of insulin pump management.
  • Identify criteria for selection of patient for dose insulin and insulin pump

Islet Cell Transplantation - Future of Hepatic vs Extra hepatic: December 12th, 2013

  • Evaluate transplantation as a treatment option for diabetes.
  • Assess pancreas transplantation
  • Restate Islet cell transplantation
  • Identify challenges to islet transplantation
  • Assess future directions of pancreas and islet cell transplantation